Esperion Therapeutics, Inc. (ESPR) — key financial figures for fiscal year 2025 (in USD), standardized from XBRL/iXBRL filings by Hub-Equity:

Revenue (FY2025)

$403.1M

Net Income/Loss (FY2025)

-$22.7M

Total Assets (FY2025)

$465.9M

Total Equity (FY2025)

-$302.0M

Cash Flows from Operating Activities (FY2025)

-$13.1M

Source: Esperion Therapeutics, Inc. 10-K filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.